(Toronto, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has completed an additional closing of its previously announced private placement. On December 28, 2016, Helix issued 1,313,000 units under the private placement for gross proceeds of approximately CAD1.58 million. On December 29, 2016, Helix issued 207,000 units under the private placement for gross proceeds of approximately CAD0.24 million. The aggregate gross proceeds raised by the Company in connection with the first and second tranches of the private placement is CAD1.82 million through the issuance of a total of 1,520,000 units.
30 December 2016